NINDS supporting Emory/UF work on myotonic dystrophy

NINDS grant will support collaboration between Gary Bassell and Eric Wang on myotonic Read more

Antios moving ahead with potential drug vs hepatitis B

Antios Therapeutics is moving ahead clinical studies of an antiviral drug aimed at hepatitis Read more

Traynelis lead researcher on CureGRIN/Chan Zuckerberg award

The CureGRIN Foundation works closely with Emory pharmacologist Stephen Traynelis, who has been investigating rare genetic disorders affecting NMDA Read more

Eric Sorscher

Beyond CF – potential byproducts of precision medicine

Just a quick comment on the potential of research being conducted by Eric Sorscher, who came to Emory from University of Alabama, Birmingham in 2015 and is now a Georgia Research Alliance Eminent Scholar. While Sorscher’s lab is working on advancing new treatments for cystic fibrosis patients who currently do not benefit from available drugs, it was intriguing to learn of potential side benefits beyond cystic fibrosis.

Cystic fibrosis is caused by mutations in the CFTR gene, which encodes a protein with important functions in cells that produce mucus, sweat, saliva, tears and digestive enzymes. But other things can impair the functioning of the CFTR protein besides genetic mutations. Namely, smoking. Read more

Posted on by Quinn Eastman in Uncategorized Leave a comment